Three ways of tackling PD-1 resistance with different modalities plus an emerging biomarker of response
A twist in the ADC moiety to think about
There is beauty in drugging intractable targets
A look at the potential missing piece in making bispecifics even better
Where a forgotten costimulator may hold the key to new developments
Encouraging new developments in the CAR-NK niche
New developments in hard to treat refractory PTCL
Continuing our coverage of the annual meeting of ASCO in Chicago I felt compelled to review the actual…
Next generation CAR-T cell therapies for solid tumours
A next generation category of KRAS inhibitors are emerging - W2W4
Off the beaten track can bring danger and delight in the unknown in equal measure
Update on Developmental Therapeutics
Where we explain what to look for in 10 posters presented at AACR23
A look at some early stage ADC molecules in the clinic
Orlando – At AACR23 the old adage of “be the first, or be the best” is well and truly…
Initial learnings on KRAS presentations at AACR23
W2W4 on the TPD front
From one compound to many competitors following in their wake!
The ever evolving selective KRAS inhibitor & degrader space
A look at an emerging early stage oncology landscape
Continuing our evaluation and exploration of another batch of early stage anti-cancer compounds either…
As we continue our new products journey evaluating early stage agents in development with data at…
Early stage new product development part 1 - seeing the wood from the trees
Half a dozen key early areas to watch out for
